Shionogi to take 10 pct stake in GSK, Pfizer HIV drug venture
TOKYO Oct 29 (Reuters) - Japan's Shionogi & Co said on Monday that it will take a 10 percent stake in Viiv Healthcare, a AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug Dolutegravir.
Shionogi, which will retain intellectual property rights to the drug, will gain one Viiv board seat and receive royalties of 15 percent to 19 percent on sales of Dolutegravir and related products, it said in a statement.
Financial terms were not disclosed. After the deal GSK will hold 76.5 percent in the venture, while Pfizer will hold 13.5 percent.
- Investigators look for motive in Malaysia plane disappearance |
- Malaysian PM says lost airliner was diverted deliberately |
- Police make third arrest in murder of Colorado socialite
- Democrats seek ways to limit Obamacare fallout after Florida defeat
- Indian Ocean poses daunting challenge in search for missing Malaysia plane